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1. Introduction 
Chronic inflammatory diseases place a social and financial burden on society. 
Glucocorticoids, a class of steroid hormones existing in almost every vertebrate, have been 
exploited for more than 60 years as a therapeutic option for the inflammatory diseases. For 
example, the therapeutic effects of synthetic glucocorticoids, first observed in rheumatoid 
arthritis (RA), led to the awarding of a Nobel prize in 1950 (Slocumb et al., 1950). Based on 
their rapid, profound and wide-ranging effects, glucocorticoids are a mainstay of treatment 
for virtually all inflammatory diseases besides RA, and now are among the most frequently 
prescribed of all medications (Hillier, 2007). Indeed, a community practice survey in 2000 
indicated that up to 1% of the entire adult population is taking systemic glucocorticoids at 
any given time (van Staa et al., 2000). Glucocorticoids have widespread systemic effects, 
particularly on the inflammation and immune response (Barnes, 2006; Chrousos, 1995). 
However, glucocorticoids are associated with dose dependent side effects, including 
diabetes mellitus, osteoporosis, weight gain, and hypertension (Huscher et al., 2009), as well 
as increased risk of cardiovascular events (Davis et al., 2007). Much effort has been expended 
identifying glucocorticoid anti-inflammatory mechanisms of action (Barnes, 2006;  Scha¨cke 
et al., 2002). Understanding of the mechanism of action of glucocorticoids is essential in 
order to devise better ways to treat inflammatory disease, ideally retaining the beneficial 
effects of glucocorticoids but not their adverse effects. 
The discovery of a glucocorticoid-induced protein that could emulate the beneficial, but not 
harmful, effects of glucocorticoids, would represent a landmark in inflammation 
translational research on a glucocorticoid alternative therapy. Glucocorticoid induced 
leucine zipper (GILZ) may be such a candidate molecule. GILZ was first identified in 1997 in 
a gene extraction library, where it was found to be dramatically induced by dexamethasone 
(D'Adamio et al., 1997). Subsequent studies, mostly utilizing forced over expression of GILZ 
have ascertained that GILZ has anti-inflammatory functions that include interactions with 
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the NF-κB and AP-1 pathways (Di Marco et al., 2007;  Mittelstadt & Ashwell, 2001), which 
closely mimics the anti-inflammatory effects of glucocorticoids. Moreover, it has recently 
been shown that GILZ is also expressed in rheumatoid arthritis (RA) synovial tissues, where 
it exerts inhibitory effects on cytokine expression, and inhibiting the expression of GILZ 
results in exacerbation of disease in a mouse model of RA. As we will summarise in this 
Chapter, GILZ is a pivotal endogenous regulator of inflammation and immune responses, 
which could represent a potential new therapeutic alternate to glucocorticoids. 
2. GILZ structure and expression  
2.1. Molecular structure of GILZ 
As shown in Fig 1, GILZ, also named TSC22 domain family protein 3 (TSC22D3),  is a 137-
amino acid protein, consisting of three major domains: the N-terminal (1-75 aa), leucine 
zipper (76-97 aa), and C-terminal domains (98-137 aa) (Beaulieu & Morand, 2011). To date, 
four isoforms of GILZ have been characterized as splice variants from the Tsc22d gene and 
named GILZ1-4 (Soundararajan et al., 2007). The leucine zipper motif of GILZ is located in 
the central part of the protein and mainly mediates the homodimerization of GILZ required 
for many of its functions (Di Marco et al., 2007), while the other two domains are responsible 
for protein-protein interactions between GILZ and transcription factors and signaling 
molecules. For example, the C-terminal of GILZ is a proline-rich region necessary for direct 
binding of GILZ to the p65 subunit of NF-κB (Di Marco et al., 2007;  Riccardi et al., 2001). In 
2001, Aryoldi and colleagues showed that the over expression of GILZ in T cells inhibits the 
activation of NF-κB by binding the p65 subunit of NF-κB and preventing its nuclear 
translocation (Ayroldi et al., 2001). GILZ was co-precipitated with the p65 subunit of NF-κB in 
macrophages stimulated with glucocorticoids, and expression of GILZ with an NF-κB reporter 
inhibits reporter activity (Berrebi et al., 2003). The N-terminal domain of GILZ directly binds 
with the upstream MAP kinase pathway activating molecule Raf-1, to inhibit its function. The 
interaction between GILZ and c-Fos and c-Jun (two constituents of AP-1) also occurs via the 
N-terminal domain of GILZ. Moreover, GILZ also binds to Ras via its tuberous sclerosis 
complex (TSC) box (61-75 aa), or even interacts with Ras and Raf together to form a trimer. 
 
Figure 1. Functional domains of GILZ 
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2.2. Expression of GILZ 
GILZ gene expression is exquisitely sensitive to induction by glucocorticoids. For example, 
in human RA synovial fibroblasts, dexamethasone (Dex), a synthetic drug derived from  
glucocorticoid class of steroid, induced a more than 10-fold increase in GILZ transcripts at a 
concentration of only 1 nM, while 100 nM dexamethasone increased GILZ mRNA by over 
100-fold (Beaulieu et al., 2010a). In vivo, exogenous glucocorticoids induce GILZ expression, 
while blockade of endogenous glucocorticoids inhibits GILZ expression in mouse, and GILZ 
expression is reduced in response to reductions in circulating cortisol in humans (Beaulieu et 
al., 2010a;  Lekva et al., 2009). The dramatic effect of glucocorticoids on GILZ is mediated via 
the direct binding of the glucocorticoid/glucocorticoid receptor (GR) complex to six 
glucocorticoid-responsive elements (GREs) located in the promoter region of the GILZ gene. 
The GILZ promoter also contains two functional forkhead-responsive elements (FHREs), 
which when bound to the transcription factor forkhead box O 3 (FoxO3) facilitate maximal 
GILZ expression induced by glucocorticoid receptor binding (Asselin-Labat et al., 2005b).  
Although GILZ expression is mainly controlled by glucocorticoids (Beaulieu et al., 2010b;  
Berrebi et al., 2003;  Eddleston et al., 2007a), it is also modulated by a variety of cytokines 
(Eddleston et al., 2007a). For example, GILZ is up-regulated by IL-10 (Berrebi et al., 2003), IL-
15 and TGF- (Ayroldi & Riccardi, 2009;  Cohen et al., 2006a), whereas GILZ is down-
regulated by IL-2 in some cell types. IL-2 can inhibit FoxO3 transcriptional activity, thus 
inhibiting glucocorticoid induced GILZ expression (Asselin-Labat et al., 2005a). Some 
inflammatory stimuli, such as tumor necrosis factor (TNF) and lipopolysaccharide (LPS), 
were also found to reduce GILZ mRNA expression in fibroblast like synoviocytes (Beaulieu 
et al., 2010b). GILZ expression can also be regulated by other anti-inflammatory molecule 
such as Annexin A1. Yang et al have reported that in Annexin A1 deficient cells, 
dexamethasone failed to significantly induce GILZ, in contrast to wild type cells (Yang et al., 
2009), which indicates a regulatory role of Annexin A1 on GILZ expression.  
Interestingly, GILZ expression is also modulated by the oxygen environment. Wang and 
colleagues recently found that hypoxia not only remarkably upregulated the expression of 
GILZ, but also significantly enhanced Dex-induced expression of GILZ in macrophages and 
the spleen of rats (Wang et al., 2011). They also reported ERK MAP kinase activity is 
involved in the upregulation of GILZ induced by hypoxia. 
To date, GILZ has been discovered to be expressed in a variety of tissues (Table 1). This 
information indicates a widespread distribution of GILZ in the human body and suggests it 
is well placed for a role as a pivotal regulator of inflammation. Moreover, growing evidence 
showed that GILZ is present in a wide range of cell types that are sensitive to 
glucocorticoids in vitro. In 1997, GILZ was first identified in T cells, in which GILZ inhibited 
T cell receptor (TCR)-mediated T cell activation (D'Adamio et al., 1997). Since then, GILZ has 
been shown to be expressed in other immune cells, including monocytes/macrophages, mast 
cells, and dendritic cells (Berrebi et al., 2003; Cohen et al., 2006b; Godot et al., 2006; Hamdi et 
al., 2007a), and to have numerous anti-inflammatory functions in these cells. These functions 
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are outlined in the following sections. Besides immune cells, GILZ has also been shown to 
express in other cell types such as epithelial cells and bone-marrow-derived mesenchymal 
stem cells (MSCs). For example, GILZ was reported to inhibit NF-κB activation in epithelial 
cells and MSCs (Eddleston et al., 2007b;  Yang et al., 2008). The studies also reported the 
expression of GILZ is necessary for dexamethasone-mediated inhibition of IL-8 production 
in respiratory epithelial cells and similarly for the dexamethasone-dependent inhibition of 
cyclo-oxygenase 2 expression in MSCs. 
 
Tissue types Expression of GILZ Reference(s)
   
Lymphoid tissue  Lymphocytes mainly from 
thymus, spleen, and lymph nodes
(Asselin-Labat et al., 2004;  D'Adamio 
et al., 1997;  Riccardi et al., 2001) 
Brain  Ubiquitously expressed in rat 
brain  
(van der Laan, 2008) 
Renal epithelium mammalian kidney epithelial 
cells 
(Soundararajan et al., 2009) 
Collecting duct  the cortical collecting duct of the 
mouse kidney 
(Robert-Nicoud et al., 2001) 
Ovaries normal ovary and epithelial 
ovary cancer  
(Redjimi et al., 2009) 
Bone tissue fetal osteoblasts, mesenchymal 
stem cells, and osteoclasts 
(Lekva et al., 2010) 
Skeletal muscle 
and cardiac tissue 
skeletal muscle tissue and 
myoblasts 
(Bruscoli et al., 2010) 
Table 1. Expression of GILZ in different tissues 
3. Effects of GILZ on the immune response 
3.1. Innate immunity 
A variety of studies suggest that GILZ has critical inhibitory effects on the activity of the 
innate immune system. In a monocytic cell line (THP-1), RANTES (also known as CCL5) 
and MIP-1 (also known as CCL3), antigen presenting MHC class II molecules, B7 co-
stimulatory molecules CD80 and CD86, and the the pathogen-associated molecular pattern 
(PAMP) receptor TLR2, are all modulated by GILZ, with an expected effect on reducing 
recruitment and activation of inflammatory cells (Berrebi et al., 2003;  Cohen et al., 2006b). 
Furthermore, in liver disease, GILZ expression in Kupffer macrophages due to 
glucocorticoids treatment reduces the production of pro-inflammatory mediators in 
response to LPS (Hamdi et al., 2007a). Besides macrophages and monocytes, GILZ is also 
expressed in human airway epithelial cells and inhibited by IL-1, TNF and interferon 
(IFN)-, and overexpression of GILZ inhibited the activation of NF-κB by IL-1 and TLR 
ligands (Eddleston et al., 2007b). Currently, it is known that GILZ expression is inhibited by 
different pro-inflammatory mediators. For example, GILZ was not produced in granulomas 
in Crohn disease and tuberculosis since the macrophages in the granulomas were activated 
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with the strong expression of the RANTES gene (Berrebi et al., 2003). By contrast, GILZ 
expression is retained in macrophages in Burkitt lymphomas, potentially contributing to the 
failure of the immune system to reject the tumor (Berrebi et al., 2003). Taken together, these 
results above indicate a wide range of inhibitory effects of GILZ in a variety of innate immune 
responses. Clearly, immune responses, such as the expression of cytokines, chemokines and 
TLRs, are highly pertinent to the known pathology of inflammatory diseases such as RA. Of 
note, no in vivo studies of the role of GILZ in regulating classic innate immune responses, such 
as responses to endotoxin or other TLR ligands, have been reported.  
3.2. Adaptive immunity 
Parallel to innate immune responses, multiple critical functions of GILZ have been found 
which regulate the activity of antigen-presenting and effector cells of the adaptive immune 
response. For example, GILZ can mediate the effects of glucocorticoids on dendritic cells 
(DCs), whose maturation and antigen presentation are impaired in the presence of increased 
GILZ. Cohen et al demonstrated that GILZ over expression altered MHC and co-stimulatory 
molecule expression, resulting in reduced antigen presentation (Cohen et al., 2006a), and 
subsequent decreased T lymphocyte activation. Moreover, the expression of GILZ is 
induced by glucocorticoids and transforming growth factor  (TGF-β) in immature DCs, and 
oral administration of glucocorticoids to patients increased the expression of GILZ in 
antigen-presenting cells (Cohen et al., 2006b). The overexpression of GILZ is also able to 
drive the development of regulatory DCs, which secrete IL-10, and prevent the production 
of pro-inflammatory cytokines induced by CD40L. Furthermore, these GILZ-expressing 
regulatory DCs were found to induced CD25hiFoxP3+CTLA-4+, IL-10 secreting T-regulatory 
cells from CD4+ T-lymphocytes (Hamdi et al., 2007b), resulting in inhibition of subsequent 
immune responses to specific antigens (Suffia et al., 2006). Regulatory T cells (Tregs) that 
inhibit activation of other T lymphocytes are generated in response to GILZ over expressing 
dendritic cells (Hamdi et al., 2007b), providing a further immunomodulatory effect of GILZ. 
This immunosuppressive effect of GILZ on DCs is extremely relevant in the context of 
inflammatory pathology since DCs determine whether antigen presentation will lead to an 
immune response or a tolerogenic response. 
Additional knowledge of the effects of GILZ in adaptive immunity arises from studies of 
modified GILZ expression in T lymphocyte cells. For example, Cannarile and colleagues 
have demonstrated increased secretion of cytokines associated with a TH2 response, such as 
IL-4, IL-10, IL-5, and IL-13, and reduced expression of cytokines associated with a TH1 
response such as IFN-γ in GILZ overexpressing cells compared with wild type T cells 
(Cannarile et al., 2006a). In their study on GILZ transgenic T lymphocytes, they found there 
was decreased expression of T-box protein 21 (T-bet) (Cannarile et al., 2006a), a transcription 
factor specifically associated with a TH1 response, and increased expression of the 
transcription factors GATA-3 and STAT6. As STAT6 modulates GATA3 which is important 
for polarization towards a TH2 phenotype (Wurster et al., 2000;  Zheng & Flavell, 1997), these 
studies indicate that the expression of GILZ promotes T lymphocyte development towards a 
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TH2 instead of TH1 phenotype. Moreover, mice transgenic for GILZ under the control of the 
CD2 promoter, that overexpresse GILZ in T cells, display a TH2-skewed phenotype, and are 
protected from the TH1-dependent model of dinitrobenzene sulfonic acid (DNBS)-induced 
colitis but exhibit an increase in the ‘allergenic’ TH2 Oxazolone-induced colitis (Cannarile et 
al., 2009). Another study investigated the levels of inflammatory mediators in wild type and 
GILZ transgenic mice induced with DNBS, and were able to demonstrate a decrease in pro-
inflammatory cytokines and NF-κB activation in GILZ transgenic mice compared to wild 
type. Furthermore, in T-cell specific GILZ transgenic mice, young animals do not exhibit a 
significant difference in thymic weight. However, there was a significant decrease in 
CD4+CD8+ double positive thymocytes. There was also a parallel increase in CD4-CD8- 
double negative and CD8+ T-cells, but no change in the CD4+ population (Delfino et al., 
2004). In the aged mice, the CD4+ population also increased in a significant manner, 
although not as dramatically as the CD8+ or the CD4-CD8- populations, signifying a 
disturbance in thymic maturation. The observation above is interesting since GILZ might 
mediate some of the glucocorticoid-triggered apoptotic effects during thymic development. 
Microarray studies also show that GILZ is expressed in resting B cells, and it is presumed 
that GILZ down-regulation facilitates B-cell activation (Glynne et al., 2000). 
4. Effect of GILZ on signalling pathways 
4.1. NF-κB pathway 
To date, much research has focused on the function of the NF-κB pathway in the anti-
inflammatory effects of glucocorticoids (Auphan et al., 1995;  DeBosscher & Haegeman, 
2009;  Gossye et al., 2009). Glucocorticoids are known as effective inhibitors of the NF-κB 
pathway, and considerable research directed at understanding the antagonistic effects of 
glucocorticoids on this pathway has been undertaken (De Bosscher et al., 2003). As shown in 
Fig 2, GILZ, significantly up regulated in the presence of glucocorticoids, participates in the 
inhibition of NF-κB by glucocorticoids through a physical interaction with the NF-κB p65 
subunit (Ayroldi et al., 2001), preventing its nuclear translocation. The inhibition of GILZ is 
independent from other IB- or Rel-related proteins, since GILZ was found to co-
immunoprecipitate with NF-κB p65 subunit in the presence or absence of IB (Ayroldi et al., 
2001). Subsequently, Yang et al demonstrated the role of GILZ in the inhibition of the 
inflammatory mediator COX-2 in MCSs in response to IL-1 and TNF-, by preventing NF-κB 
p65 subunit nuclear transport (Yang et al., 2008). Similarly, the mechanism of GILZ-NF-κB 
mediated inhibition of COX-2 transcription has been shown in epithelial cells (Eddleston et 
al., 2007b). The inhibition of NF-κB by GILZ has also been demonstrated in vivo, in a transgenic 
mouse model in which GILZ expression is driven by the CD2 promoter, resulting in the 
overexpression of GILZ in thymocytes (Delfino et al., 2006). When subjected to T-cell receptor-
triggered apoptosis, the nuclear translocation and DNA binding of NF-κB were impaired in T 
cells from GILZ transgenic mice, whereas the translocation of transcription factors belonging 
to the NFAT family was not affected. All the findings above arouse interest in GILZ and its 
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function in the pathogenesis of NF-B–related inflammatory diseases. For example, GILZ 
transgenic mice demonstrated reduced NF-κB activation in spinal cord injury in comparison to 
wild type mice, and overexpression of GILZ protects TH1 inflammatory responses in colitis 
associated with inhibition of nuclear and phosphorylated p65 (Cannarile et al., 2009; Esposito et 
al. 2011). Moreover, Srinivasan and colleagues have described a novel NF-κB p65-binding 
GILZ-derived peptide which exhibited therapeutic potential as a small molecule NF-κB 
inhibitor in experimental autoimmune encephalomyelitis (EAE), a model of human multiple 
sclerosis (Srinivasan & Janardhanam, 2011a).  
4.2. AP-1 pathway 
The transcription factor AP-1 is another major participant in inflammatory and immune 
responses (Adcock & Caramori, 2001). AP-1, as a heterodimer of the c-Fos and c-Jun 
proteins, can be phosphorylated to significantly increase its transcriptional activity. The 
direct inhibitory effects of the glucocorticoid-glucocorticoid receptor complex on AP-1 
signaling are well documented (De Bosscher et al., 2003). It is also known that 
glucocorticoids lead to the repression of mitogen-activated protein kinase (MAPK) activity 
and hence AP-1 activation through the expression of phosphatases that exert inhibitory 
interactions with various MAPK members (Aeberli et al., 2006). Of interest, Mittelstadt and 
colleagues showed direct binding of GILZ to the AP-1 components c-Jun and c-Fos (Fig 2) in 
Jurkat cells (an immortalized line of T cells) (Mittelstadt & Ashwell, 2001). The paper also 
showed GILZ is critical for the regulation of FasL expression in response to glucocorticoids. 
FasL is a promoter containing NFAT binding elements and under regulation of the 
NFAT/AP-1 complex signalling. FasL promoter and its enhancer elements, early growth 
response factor (Erg) -2 and Erg-3 were inhibited by transient transfection of GILZ in 
Jurkat cells. The authors demonstrated that c-Fos and c-Jun do in fact interact with N-
terminal, but not the LZ or PER domains, of GILZ. Furthermore, Ayroldi et al. confirmed 
the interaction of GILZ with c-Fos and c-Jun, and further showed that GILZ expression 
interferes with c-Fos transcription in response to anti-CD3 stimulation of IL-2, but not c-
Jun, and also by negatively interfering with upstream signalling of Raf-1-ERK pathway 
(Ayroldi et al., 2002).  
4.3. MAP kinase pathways 
The MAP kinase family consists of extracellular signal-regulated kinase (ERK), p38 kinase, 
and JNK, all of which can be activated by upstream molecules such as Ras and Raf-1 
(Rincon, 2001) and all of which phosphorylate downstream proteins in the respective 
cascades to regulate expression of a variety of genes related to inflammation, cell 
proliferation, differentiation and apoptosis. GILZ has also been shown to bind to both Raf-1 
(Ayroldi et al., 2002) and Ras (Ayroldi et al., 2007) and thereby to modulate downstream 
signalling (Fig 2). Ayroldi and colleagues reported that GILZ overexpression in anti-CD3-
stimulated T cells can bind to Raf-1, which inhibits phosphorylation of Raf-1 and results in 
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suppression of MEK and ERK1/2 phosphorylation (Ayroldi et al., 2002). They also found that 
GILZ can bind to Raf-1 via the NH2-terminal region of GILZ and Ras via the TSC box of 
GILZ. The interaction of GILZ with Ras or Raf-1 has been shown to be dependent on the 
activation of Ras, where GILZ will bind predominately to Raf-1 in the absence of active Ras. 
However, as Ras is activated, Raf-1 will bind to Ras to a stronger degree than it will bind to 
GILZ. Furthermore, the affinity of GILZ to Ras will also increase, leading to predominately 
GILZ-Ras complexes (Ayroldi, 2007). GILZ may also form a trimer with both Ras and Raf-1, 
and this is also dependent on Ras activation. All the results above suggest that GILZ inhibits 
cell activation and inflammation via regulation of MAPK signaling molecules.  
4.4. PI3K/Akt and apoptotic signalling pathways  
The inhibition by GILZ of Ras and Raf-1 also decreases the activation of another 
downstream signalling pathway, the PI3 kinase (PI3K)/Akt pathway, which is involved in 
cell survival as well as activation. Recent studies have uncovered a crucial role for FoxO3 in 
mediation of PI3K/Akt pathway. In the cell, non-phosphorylated FoxO3 migrates into the 
nucleus and up-regulates several mediators of cell cycle progression, such as G1/S-specific 
cyclin-D1, p27KIP1 (also known as cyclin-dependent kinase inhibitor 1B), Fas ligand (also 
known as tumor necrosis factor ligand superfamily member 6) and Bim (also known as Bcl-
2-like protein 11), to inhibit cell proliferation (Schmidt et al., 2002). Activation of Akt leads to 
the phosphorylation of FoxO3, which results in the nuclear exclusion of FoxO3 and thus 
leads to the inhibition of their cognate transcriptional targets. Interestingly, the gene 
encoding GILZ has been identified as a transcriptional target of FoxO3 (Asselin-Labat et al., 
2005b). Other studies have demonstrated that GILZ can inhibit its own expression through a 
negative feedback effect to promote nuclear exclusion of FoxO3 shown in Fig 2 (Latre de 
Late et al., 2010). However, until now, the net effect of the PI3K/Akt-FoxO3–GILZ regulatory 
loop on cell proliferation has not yet been clearly defined. 
GILZ has also been shown to modulate the expression of a variety of apoptosis pathway 
proteins in accordance with the observations that GILZ can prevent anti-CD3 mediated 
apoptosis (D'Adamio et al., 1997). Asselin-Labat and colleagues showed that an increase in 
GILZ expression down-regulates the expression of Bim, a pro-apoptotic member of the Bcl-2 
family, but has no effect on Bcl-xL protein, an anti-apoptotic Bcl-2 family protein, to prevent 
apoptosis. In the same study, they demonstrated that knockdown of GILZ accelerates IL-2-
deprivation-mediated apoptosis in the IL-2-dependent, CTLL-2 cell line, through increased 
levels of Bim (Asselin-Labat et al., 2004). Furthermore, they showed that GILZ acts on Bim 
through the transcriptional factor FoxO3. Using a Bim-promoter-luciferase construct, GILZ 
expression was shown to repress Bim transcription, and these effects were abrogated with 
the co-expression of FoxO3 (Asselin-Labat et al., 2004). However, it had been previously 
shown in CD4+CD8+ double positive T cells that overexpression of GILZ leads to an increase 
in the spontaneous apoptosis, and an interaction with, and reduction of, Bcl-xL. 
Furthermore, GILZ expression was associated with an increase in the activation of extrinsic 
apoptotic caspases -3 and -8, but not caspase-9, involved in the mitochondrial/cytochrome C 
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pathway (Delfino et al., 2004). The authors suggested that NF-κB inhibition is the 
mechanism by which TCR mediated apoptosis is inhibited by GILZ in over expression 
models, and that NF-κB may be involved in control of Bcl-xL (Delfino et al., 2006). Whilst the 
mechanism of GILZ in regulation of cell apoptosis has yet to be well understood, it follows 
the general trend of GILZ to display a dual activity in regards to apoptosis and cell survival. 
4.5. Other non-inflammatory signalling pathways 
In addition to mediating glucocorticoid effects in inflammation and immunity, GILZ may 
also play a critical role in non-immune function such as adipogenesis and osteogenesis. For 
example, Shi et al reported that GILZ directly binds to CCAAT/enhancer-binding protein 
(C/EBP) DNA binding sites in the PPAR-2 promoter, with consequent inhibition of 
mesenchymal cell adipogenesis (Shi et al., 2003). Previously, glucocorticoids had been shown 
to activate C/EBP directly, and therefore promote PPAR-2 expression and adipocyte 
differentiation (Shi et al., 2003). This observation thus suggests a potential role of GILZ as a 
direct transcriptional repressor of gene expression in a direction opposite to the effects of 
Glucocorticoids. Of note, this is in contrast to the effects of GILZ binding to pro-inflammatory 
transcription factors where it mimics the effects of glucocorticoids. Moreover, as PPAR-2 is a 
key regulator of adipogenesis, GILZ’s prevention of C/EBP action inhibits adipogenesis, and 
thereby promotes osteogenesis (Zhang et al., 2008b), again an effect opposite to those of 
glucocorticoids which promote osteoporosis. The findings offer the suggestion of a possible 
GILZ-based therapy wherein GILZ exhibits beneficial glucocorticoid anti-inflammatory 
actions without the negative side effects of adiposity and osteoporosis.  
 
Figure 2. Roles of GILZ as a mediator in immune signaling pathways 
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NF-κB, activated by a variety of inflammatory stimulation, translocates into the nucleus and 
binds to target genes encoding pro-inflammatory factors. Glucocorticoid bound to the 
receptor GR can directly interact with NF-κB to prevent its nuclear translocation. In 
addition, the GC/GR complex can translocate into the nucleus and bind to glucocorticoid 
response elements on the GILZ gene to induce GILZ expression. GILZ in turn binds to NF-
κB and prevents its nuclear translocation. GILZ can also directly bind to c-Jun and c-Fos, 
two constituents of AP-1, to inhibit their transcriptional activity and gene expression of pro-
inflammatory molecules. The location, in the cytoplasm or nucleus, where GILZ binds to 
AP-1 subunits is still unknown. In the cytoplasm, GILZ also modulates cell survival by 
blocking Ras activation and the downstream PI3K/Akt signaling pathway. GILZ binds and 
inhibits Ras and Raf phosphorylation and thus inhibits downstream MEK-1/2 and ERK-1/2 
activation. As part of a negative feedback loop, GILZ prevents nuclear translocation of 
FoxO3, which is in turn a key transcriptional factor to upregulate GILZ gene expression. 
5. Effect of GILZ on inflammatory and autoimmune diseases 
The reported actions of GILZ suggest GILZ may exert anti-inflammatory effects in immune 
and inflammatory diseases. Studies in animal disease models, or in human pathology, 
remain limited, but favour a role for GILZ as a modulator of immune-inflammatory 
responses. For example, Cannarile and colleagues reported GILZ effects on delayed-type 
hypersensitivity (DTH) responses in the GILZ transgenic mouse (Cannarile et al., 2006b). In 
response to ovalbumin (OVA) immunization, GILZ overexpression mice exhibited 
significantly less swelling than wild type control, which indicates the essential role of GILZ 
in T cells in inhibiting TH1 dependent DTH responses. The authors also investigated a 
murine model of colitis, in which it was shown that significant inhibition was observed in 
mice overexpressing GILZ in T cells (Cannarile et al., 2009). In addition, studies of these T 
cells showed reduction of the TH1 cytokine IFN-. Moreover, colon lysates from GILZ 
overexpressing mice have lower total and phosphorylated Ser536 NF-κB p65, which 
indicates that GILZ overexpression in T cells protects mice from TH1-mediated colitis disease 
by inhibition of NF-κB activity.  
Recently, Beaulieu and colleagues investigated the role of endogenous GILZ in RA (Beaulieu 
et al., 2010a). GILZ was potently induced by glucocorticoids in cultured human RA synovial 
cells in vitro, and in murine arthritis in vivo. GILZ silencing by in vivo siRNA administration 
resulted in increased severity of the collagen-induced model of RA in mice, and in parallel 
GILZ overexpression inhibited chemokine and cytokine expression in human synovial cells. 
These results suggest GILZ as a key endogenous regulatory molecule in RA. Another study 
showed that GILZ was noticeably absent in granulomas in Crohn disease and tuberculosis 
(Berrebi et al., 2003), which suggests inhibitor regulation of GILZ in the presence of chronic 
inflammatory disease, while human asthma patients demonstrated increased GILZ 
expression in response to glucocorticoid therapy (Kelly et al., 2011).  
GILZ is also reported to attenuate experimental autoimmune encephalomyelitis (EAE), a 
disease model of human multiple sclerosis. Srinivasan and colleagues demonstrated that 
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delivery of a GILZ-derived peptide is protective against EAE in mice (Srinivasan & 
Janardhanam, 2011b). The GILZ fragment they isolated, containing a proline rich domain, can 
directly interact with p65 NF-B, thereby inhibiting p65 translocation from activated human 
CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs) (Srinivasan & 
Janardhanam, 2011a). As T cells are a major target of glucocorticoids in EAE (Wust et al., 2008), 
these data provide further evidence that exogenous GILZ could exert therapeutically useful 
anti-inflammatory properties.  
6. Perspective and expectations: GILZ as a glucocorticoid sparing target 
GILZ, a molecule mainly modulated by glucocorticoids, play a pivotal role in the regulation 
of inflammation and immune responses. Expressed in multiple cells and tissues, GILZ 
inhibits the expression of a variety of inflammatory mediators and modulates the immune 
response. In this chapter, we have summarised GILZ structure and function, the effects of 
GILZ in immune responses, and its interaction with a number of key transduction pathways 
pivotal to the pathogenesis of inflammatory diseases. The more recent observations that 
GILZ exerts immunomodulatory and anti-inflammatory effects in vivo that mimic the 
inhibitory actions of glucocorticoids strongly suggests GILZ is a potential substitute for 
glucocorticoids in the therapy of inflammatory diseases. 
As we have noted, currently a number of important anti-inflammatory molecules, such as 
Annexin A1 and MKP-1, are induced by glucocorticoids, and evidence that synthetic 
glucocorticoids lose their effectiveness in the absence of these molecules has been adduced 
(Furst et al., 2007;  Ralph & Morand, 2008;  Yang et al., 2009;  Yang et al., 2004;  Yang et al., 
2006). Attention to the molecules that glucocorticoids amplify the expression of will permit 
discovery of the means to develop a surrogate for glucocorticoids’ beneficial impact on 
immune activation without their toxicity. Importantly, the presence of GILZ exerts immune 
and inflammation modulatory effects in the absence of glucocorticoids. A GILZ-based 
therapeutic approach, therefore, could potentially offer profound glucocorticoid-like 
regulatory effects in autoimmune disease. Investigation of the metabolic effects of any GILZ-
based therapy is required in order to ensure that the undesirable effects of glucocorticoids 
are not recapitulated. Early results are encouraging in this regard. In mesenchymal stem 
cells, differentiation towards osteogenic precursors is enhanced by GILZ, whereas silencing 
of GILZ reduced osteogenic differentiation (Zhang et al., 2008a), suggesting that a GILZ 
therapy might have protective rather than harmful effects on bone. GILZ expression was 
also associated with osteoblast development, and GILZ silencing increased osteoblast 
expression of OPG and RANKL in favour of osteoclastogenesis (Lekva et al., 2010), further 
suggesting that GILZ-based therapy might have a bone-protective effect. Studies of the role 
of GILZ in glucocorticoid-induced osteoporosis in vivo are eagerly awaited.  
GILZ-based therapies could be based around the administration of recombinant protein or 
NF-κB binding peptides. As we have introduced above, Srinivasan and colleagues have 
described a novel NF-κB p65 binding GILZ peptide which exhibited therapeutic potential as 
a NF-κB inhibitor in EAE (Srinivasan & Janardhanam, 2011b). Alternatively, a gene therapy 
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approach, which has already been successfully used in vivo to suppress arthritis via delivery 
of the anti-inflammatory cytokine IL-10 (Apparailly et al., 2002), could be applied to GILZ. 
Inducing GILZ expression other than through the use of glucocorticoids, for example by 
modifying activity of the transcription factor FoxO3, could represent a further means to 
increase available GILZ protein, as could inhibition of the as-yet unidentified mechanisms of 
GILZ protein turnover. Finally, structure-function analysis of the molecules with which 
GILZ interacts in order to achieve its immune modifying effects could reveal targets for 
synthetic GILZ mimetics. Although considerable work remains, the first proof of concept 
studies of an in vivo GILZ-based therapeutic approach is under development in the authors’ 
laboratory (unpublished observations).  
In conclusion, glucocorticoids remain among the most widely used drugs in human 
diseases, and in particular in autoimmune disease. Their effectiveness is increasingly well 
understood, based on their effects on inflammatory signal transduction, but their use is 
constrained by toxicity, which also relates to their specific physiological actions. GILZ is a 
key molecule in glucocorticoid biology, which now represents a candidate mediator of 
glucocorticoid regulation of immune and inflammatory responses, and deserves further 
investigation. 
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